Status:
UNKNOWN
Intestinal Fatty Acid-binding Protein (I-FABP) Levels in Pediatric Celiac Patients
Lead Sponsor:
Schneider Children's Medical Center, Israel
Conditions:
Celiac Disease in Children
Eligibility:
All Genders
Up to 17 years
Brief Summary
A prospective, longitudinal study meant to compare blood levels of I-FABP in pediatric celiac patients during diagnosis to levels under gluten free diet, it's correlation with traditional serology tes...
Detailed Description
I-FABP is a reliable marker for intestinal damage and has been proved to respond more swiftly than traditional serology to enterocyte injury in celiac patients who do not a gluten free diet. In this s...
Eligibility Criteria
Inclusion
- Children undergoing endoscopy for diagnosis of celiac disease, with elevated serology (TTG more than 3 times the norm), and whose histological Marsh score is 2 or higher.
Exclusion
- Diseases known to cause elevation in I-FABP levels: Bowel ischemia, inflammatory bowel disease, Primary Biliary Cholangitis, liver failure, biliary duct obstruction, liver malignancy.
- Bowel trauma or abdominal surgery or acute gastroenteritis in the last 3 months
- NSAID use in the last week.
- Intensive daily physical activity (over 1 hour) in the 2 days prior to endoscopy.
- Known genetic disorders (such as Down's syndrome).
- Patients whose TTG was elevated but lower than 3 times the normal range.
Key Trial Info
Start Date :
November 1 2017
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
August 1 2020
Estimated Enrollment :
70 Patients enrolled
Trial Details
Trial ID
NCT03244254
Start Date
November 1 2017
End Date
August 1 2020
Last Update
October 4 2017
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Schneider Children's Medical Center of Israel
Petah Tikva, Israel